Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In a phase 2, placebo-controlled trial, nemolizumab, an antibody against interleukin-31 receptor A, reduced pruritus in patients with moderate-to-severe atopic dermatitis. These findings support the role of interleukin-31 in the pathophysiology of atopic dermatitis.
Atopic dermatitis is a chronic pruritic, inflammatory skin disease that is trigg...
Alternative Titles
Full title
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1873722496
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1873722496
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1606490
